# A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

> **NCT06318273** · PHASE1 · RECRUITING · sponsor: **AbbVie** · enrollment: 230 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** ABBV-969

## Key facts

- **NCT ID:** NCT06318273
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-08
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06318273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06318273, "A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06318273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*